IAMA-6 + NKCC1 portfolio

IAMA-6 + NKCC1 portfolio refers to a collection of small molecule inhibitors developed by IAMA Therapeutics that target the Na-K-Cl cotransporter 1 (NKCC1), also known as SLC12A2. The lead candidate in this portfolio, IAMA-6, is an orally bioavailable, selective NKCC1 antagonist currently in Phase 1 clinical development. The broader portfolio includes preclinical follow-on assets such as IAMA-X. These compounds are designed to modulate intracellular chloride concentrations to restore the balance between excitatory and inhibitory neurotransmission, which is often disrupted in various central nervous system conditions. The primary therapeutic focus for this portfolio includes neurodevelopmental disorders such as autism spectrum disorder (ASD), as well as refractory epilepsy and other neurological conditions characterized by GABAergic dysfunction.

Other names

NKCC1 portfolioNKCC-1 portfolioNKCC 1 portfolioIAMA-6 & NKCC1 portfolio